Skip to main content
. Author manuscript; available in PMC: 2016 Jan 5.
Published in final edited form as: Nat Rev Clin Oncol. 2014 Sep 30;11(11):637–648. doi: 10.1038/nrclinonc.2014.159

Figure 1.

Figure 1

Immunoconjugate modules. Immunoconjugates are composed of three different components: a monoclonal antibody, a therapeutic entity, and a linker that joins the antibody and the therapeutic agent. Using this basic immunoconjugate model, different therapeutic entities, including pharmacologics, radioactive agents, and toxins, can be delivered to the cancer cells.